The TheraBionic P1 device was approved by the FDA in September 2023 for the treatment of advanced liver cancer in adult patients for whom first- and second-line treatment therapies have failed, according to a Dec. 18 news release from the institute.
The portable device, co-invented by Karmanos President and CEO Boris Pasche, MD, PhD, targets liver cancer cell growth by delivering modulated radiofrequencies through a handheld antenna.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
